New User:

Forgot your password?

Stock Market & Financial Investment News

News For BMY;PFE;DUF;CG;HLF;CALM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 >>
November 19, 2015
06:46 EDTPFECiti not seeing how Treasury can stop Pfizer, Allergan deal
Citi analyst Liav Abraham says he struggles to see what the Treasury can do to stop Pfizer's (PFE) potential acquisition of Allergan (AGN). The Treasury's plans announced yesterday to implement further actions to curb tax inversions were likely spurred by the "imminent announcement" of a Pfizer, Allergan merger, Abraham tells investors in a research note. The developments were likely factored into Pfizer and Allergan's assumptions when entering into merger discussions, the analyst adds. He expects a deal to be announced over the near term and keeps a Buy rating on Allergan with a $360 price target. Bloomberg reported last night that Pfizer is nearing an acquisition of Allergan at $370-$380 per share. The Botox maker closed yesterday at $310.38.
06:06 EDTPFEAllergan weekly volatility elevated into reports of near deal with Pfizer
Subscribe for More Information
05:29 EDTPFEServier exercises licensing option with Cellectis for UCART19
Subscribe for More Information
November 18, 2015
20:00 EDTPFEPfizer nears deal for Allergan at $370-$380 per share, Bloomberg says
Subscribe for More Information
19:00 EDTPFEPfizer nearing acquisition of Allergan at $370-$380 per share, Bloomberg says
Subscribe for More Information
17:00 EDTPFETreasury Department to release new 'guidance' deterring tax inversions, WSJ says
Subscribe for More Information
16:24 EDTCGBlackstone, Carlyle, KKR potential buyers of Armacell, Reuters says
Britain's Charterhouse has established a Friday deadline for bids on its insulation materials company Armacell, which may be valued at up to $1.06B, reports Reuters, citing sources. The business has attracted interest from private equity firms, with Blackstone (BX), Carlyle (CG), and KKR (KKR) "cited as potential buyers," according to the report. Reference Link
12:01 EDTBMYBristol-Myers Squibb says Opdivo data shows 'superior' overall survival
Subscribe for More Information
08:11 EDTPFE, BMYIMS Health forecasts global drug spending to increase 30% by 2020 to $1.4T
Subscribe for More Information
08:06 EDTPFEPfizer says Phase 3 XALKORI trial shows 'positive' results
Subscribe for More Information
07:02 EDTPFEMerck KGaA, Pfizer win FDA breakthrough therapy designation for Avelumab
Subscribe for More Information
06:09 EDTPFEValeant's Addyi sees hardly any sales, Bloomberg says
Subscribe for More Information
November 17, 2015
16:42 EDTHLFJustice Department announces criminal charges against supplement maker USPlabs
The U.S. Department of Justice, along with partners at the Food and Drug Administration, Federal Trade Commission, Postal Inspection Service, and Internal Revenue Service, announced a "nationwide sweep" targeting more than 100 makers and marketers of dietary supplements. The agencies noted, "The actions discussed today resulted from a year-long effort, beginning in November 2014, to focus enforcement resources in an area of the dietary supplement market that is causing increasing concern among health officials nationwide. In each case, the department or one of its federal partners allege the sale of supplements that contain ingredients other than those listed on the product label or the sale of products that make health or disease treatment claims that are unsupported by adequate scientific evidence." Among the cases announced Tuesday is a criminal case charging USPlabs and several of its corporate officers with various counts associated with the unlawful sale of dietary supplements, obstruction of an FDA proceeding, and conspiracy to commit money laundering. The Department also filed in the past week five civil cases seeking injunctive relief against a number of businesses and individuals that allegedly sold supplements as disease cures or that were otherwise in violation of the law. The cases involve various entities, including Vibrant Life, Viruxo, Optimum Health, Bethel Nutritional, VivaCeuticals, and Regeneca, said the agency. Note that shares of GNC (GNC), Herbalife (HLF), Vitamin Shoppe (VSI), and Natural Health (NHTC) all slipped Tuesday following early reports of criminal charges in the dietary supplement space. Reference Link
15:10 EDTHLFDOJ files indictment against USPLabs over Supplements, FDA Law Blog says
Shares of GNC Holdings (GNC), Vitamin Shoppe (VSI), and Herbalife (HLF) were all weak this afternoon on concerns that they would be the target of the FDA's action. Reference Link
13:09 EDTHLFHerbalife says not aware of being named in DOJ supplement action, Bloomberg says
Subscribe for More Information
12:35 EDTHLFHerbalife puts active on headlines of DOJ briefing on supplement actions
Herbalife November 47 and 50 puts are active on total put volume of 9,800 contracts (2,400 calls) following Bloomberg headlines of DOJ briefing on supplement actions. November put option implied volatility is at 113, December is at 55; compared to its 52-week range of 34 to 126. Active put volume suggests traders taking positions for wide price movement.
12:28 EDTHLFGNC, Vitamin Shoppe, Herbalife at lows following DOJ supplement advisory
The Department of Justice said in a media advisory that it plans to announce at 3:30 pm today its actions related to dietary supplements sales and unlawful ads. Following the press advisory, shares of GNC Holdings (GNC), Vitamin Shoppe (VSI) and Herbalife (HLF) are at session lows, though none of the companies were named in the advisory.
11:35 EDTCGFinancing backing Carlyle's purchase of Symantec's Veritas pulled, Reuters says
Subscribe for More Information
10:47 EDTBMYBristol-Myers strength attributed to sale chatter
The move higher in shares of Bristol-Myers (BMY) is being attributed by traders to chatter of a sale. The stock is up 2%, or $1.06, to $66.08 in morning trading. The unconfirmed talk has the company possibly approaching Gilead (GILD) about buyout interest. Bristol's market capitalization is just above $110B while Gilead's is just above $150B. Shares of Gilead are up 74c to $104.55.
05:22 EDTPFEStocks with implied volatility movement; P PFE
Stocks with implied volatility movement; Pandora (P) 104, Pfizer (PFE) 29 according to iVolatility.
1 | 2 | 3 | 4 | 5 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use